Incyte (INCY) Tops Q3 EPS by 46c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Incyte (INCY) Weakness Seen Related to OPZELURA Sample 'Texture Issues' - Mizuho
November 2, 2021 11:02 AM EDTMizuho Securities analyst Mara Goldstein weighed in on Incyte (NASDAQ: INCY) following Q3 results and its earnings call. The analyst believes the weakness is likely related to management's comment on a texture issue associated with OPZELURA' (ruxolitinib cream) samples for atopic dermatitis (AD) and is under investigation... More
